Larimar Therapeutics (LRMR) is a pre-revenue clinical-stage biopharmaceutical company developing nomlabofusp for Friedreich's ataxia. Under a liquidation lens as of December 31, 2025, recovery to equity is thin and primarily dependent on the liquid asset base. Total assets of $145.8M are dominated by current assets of $142.0M, comprising cash and cash equivalents of $85.4M, marketable securities (available-for-sale debt securities) of $51.4M, prepaid and other current assets of $5.2M, and accrued interest of $0.7M. Applying standard haircuts: cash at 100% yields $85.4M; marketable securities at 95% (short-duration AFS) yield approximately $48.9M; prepaid/other current at 0-10% yield near zero. Non-current assets of $3.8M consist of operating ROU asset ($2.1M, 0% recovery), PP&E net of $0.6M (50-60% recovery, approximately $0.3M), restricted cash of $0.6M (100%), and other non-current assets of $0.5M (uncertain). Total haircutted asset pool is approximately $135-136M. On the liability side, current liabilities of $64.8M are held at face: accounts payable $5.2M, accrued liabilities $58.5M (which includes a large increase from $21.0M at year-end 2024 per the prior Q3 filing data, driven by nomlabofusp manufacturing prepayments and clinical trial accruals), and employee-related liabilities $3.8M (included within accrued liabilities current). Operating lease obligations under ASC 842 total $4.1M present value ($1.1M current, $3.0M non-current), which survive a liquidation wind-down. Total liability stack at face is approximately $67.8M. Approximate liquidation recovery to equity: $135M haircutted assets minus $67.8M liabilities equals approximately $67M, versus book equity of $78.1M — representing a roughly 14% liquidation discount to book. This is materially positive, not negative, because the asset base is almost entirely cash and near-cash instruments with no goodwill, no capitalized intangibles, and no debt. The primary risk to this estimate is the $58.5M accrued liabilities balance, which surged from roughly $21M at September 30, 2024 — driven by manufacturing commitments for commercial-scale nomlabofusp supply build (the filing discloses $32.9M in nomlabofusp manufacturing cost increases in the nine months ended September 30, 2025 alone). If additional unfunded manufacturing or CRO obligations sit off-balance sheet or within the accrued balance at amounts exceeding booked accruals, recovery narrows. The MFFAIS CLV/LLV/OLV of $17.7M appears significantly understated relative to the filed balance sheet; this likely reflects a stale or discounted model input rather than the current balance sheet. The company had an accumulated deficit of $434.8M and a full valuation allowance of $232.8M against gross deferred tax assets — both confirming the going-concern context, though irrelevant to liquidation recovery directly. A November 2025 lease amendment adding 7,107 square feet in Bala Cynwyd has not yet commenced for accounting purposes; no ROU asset or liability is recorded. When it does commence, it will add to the lease liability stack. Filing discusses manufacturing commitments and CRO obligations in MD&A that are not separately broken out in XBRL as distinct contractual liability tags.
▼ Community Notes